Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: A GEMCAD group study

Annals of Oncology

Volumn 25, Issue 2, 2014, Pages 398-403

  Custodio, A ^a   Moreno Rubio, J ^a   Aparicio, J ^b   Gallego Plazas, J ^c   Yaya, R ^d   Maurel, J ^e   Higuera, O ^a   Burgos, E ^a   Ramos, D ^b   Calatrava, A ^d   Andrada, E ^c   Lopez R ^a   Moreno, V ^a   Madero, R ^a   Cejas, P ^a   Feliu, J ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^d Valencian Autonomous Government   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

Author keywords

Adjuvant chemotherapy; Colon cancer; Early stage; Oxaliplatin; Peripheral neuropathy; Single nucleotide polymorphism

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CAPECITABINE; CYCLIN H; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GENOMIC DNA; OXALIPLATIN; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; CCNH PROTEIN, HUMAN; PLATINUM COMPLEX; TUMOR PROTEIN;

ABCG2 GENE; ADJUVANT THERAPY; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER STAGING; CCNH GENE; CELL CYCLE REGULATION; COLON CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DNA REPAIR; DOSE RESPONSE; DRUG DETOXIFICATION; DRUG DOSE REDUCTION; DRUG EXCRETION; DRUG WITHDRAWAL; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; VALIDATION PROCESS; VERY ELDERLY; YOUNG ADULT; ADJUVANT CHEMOTHERAPY; CHEMICALLY INDUCED; COLONIC NEOPLASMS; GENETIC ASSOCIATION; GENETICS; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; CYCLIN H; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84893399079     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt546     Document Type: Article

References (25)

1. André T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27(19): 3109-3116.
2. Haller DG, Tabernero J, Maroun J et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011; 29(11): 1465-1471.
3. Argyriou AA, Cavaletti G, Briani C et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study of 170 patients with colorectal cancer. Cancer 2013; 119(2): 438-444.
4. Park SB, Lin CSY, Krishnan AV et al. Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist 2011; 16(5): 708-716.
5. Argyriou AA, Velasco R, Briani C et al. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. Ann Oncol 2012; 23(12): 3116-3122.
6. Ye F, Liu Z, Tan A et al. XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis. Cancer Chemother Pharmacol 2013; 71(3): 733-740.
7. Peng Z, Wang Q, Gao J et al. Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis. Cancer Chemother Pharmacol 2013; 72(2): 305-314.
8. Fariña Sarasqueta A, van Lijnschoten G, Lemmens VE et al. Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers?. Mol Diagn Ther 2011; 15(5): 277-283.
9. Inada M, Sato M, Morita S et al. Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. Int J Clin Pharmacol Ther 2010; 48(11): 729-734.
10. Kanai M, Yoshioka A, Tanaka S et al. Association between glutathione S-transferase π 105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy. Cancer Epidemiol 2010; 34(2): 189-193.
11. McLeod HL, Sargent DJ, Marsh S et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol 2010; 28 (20): 3227-3233.
12. Kweekel DM, Antonini NF, Nortier JW et al. Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array. Br J Cancer 2009; 101(2): 357-362.
13. Argyriou AA, Antonacopoulou AG, Scopa CD et al. Liability of the voltage-gated sodium channel gene SCN2A R19K polymorphism to oxaliplatin-induced peripheral neuropathy. Oncology 2009; 77(3-4): 254-256.
14. Basso M, Modoni A, Spada D et al. Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity. Cancer Chemother Pharmacol 2011; 67(5): 1179-1187.
15. Theile D, Grebhardt S, Haefeli WE et al. Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. Biochem Pharmacol 2009; 78(11): 1366-1373.
16. Meyer K, Ueland PM. Use of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for multiplex genotyping. Adv Clin Chem 2011; 53: 1-29.
17. Klopfleisch R, Weiss AT, Gruber AD. Excavation of a buried treasure-DNA, mRNA, miRNA and protein analysis in formalin fixed, paraffin embedded tissues. Histol Histopathol 2011; 26(6): 797-810.
18. Baek KK, Lee J, Park SH et al. Oxaliplatin-induced chronic peripheral neurotoxicity: a prospective analysis in patients with colorectal cancer. Cancer Res Treat 2010; 42(4): 185-190.
19. Won HH, Lee J, Park JO et al. Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer 2012; 118(11): 2828-2836.
20. Lolli G, Johnson LN. CAK-cyclin-dependent activating kinase: a key kinase in cell cycle control and a target for drugs?. Cell Cycle 2005; 4(4): 572-577.
21. Ta LE, Espeset L, Podratz J et al. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 2006; 27(6): 992-1002.
22. Wu G, Cao J, Peng C et al. Temporal and spatial expression of cyclin H in rat spinal cord injury. Neuromolecular Med 2011; 13(3): 187-196.
23. Ashraf T, Kis O, Banerjee N et al. Drug transporters at brain barriers: expression and regulation by neurological disorders. Adv Exp Med Biol 2012; 763: 20-69.
24. Campa D, Müller P, Edler L et al. A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis. Int J Cancer 2012; 131(12): 2920-2928.
25. Lee KH, Chang HJ, Han SW et al. Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer. Cancer Chemother Pharmacol 2013; 71(4): 843-851.